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Abstract
The spread of the Zika virus (ZIKV) in the Americas led to large outbreaks across the region
and most of the Southern hemisphere. Of greatest concern were complications following acute
infection during pregnancy. At the beginning of the outbreak, the risk to unborn babies and
their clinical presentation was unclear. This report describes the methods and results of the
UK surveillance response to assess the risk of ZIKV to children born to returning travellers.
Established surveillance systems operating within the UK – the paediatric and obstetric sur-
veillance units for rare diseases, and national laboratory monitoring – enabled rapid assess-
ment of this emerging public health threat. A combined total of 11 women experiencing
adverse pregnancy outcomes after possible ZIKV exposure were reported by the three surveil-
lance systems; five miscarriages, two intrauterine deaths and four children with clinical pre-
sentations potentially associated with ZIKV infection. Sixteen women were diagnosed with
ZIKV during pregnancy in the UK. Amongst the offspring of these women, there was
unequivocal laboratory evidence of infection in only one child. In the UK, the number and
risk of congenital ZIKV infection for travellers returning from ZIKV-affected countries is
very small.
Introduction
In February 2015, health authorities of Caxias, a municipality in the North eastern state of
Maranhao in Brazil, reported an outbreak of an unidentified febrile illness characterised by
a rash and joint pain, affecting hundreds of people. Viral infections common in this area
such as Chikungunya virus were quickly excluded; however, it took several months for the
pathogen to be identified. Almost 7000 cases had been notified when an association with
Zika virus (ZIKV) was confirmed in May 2015 and the Ministry of Health reported autoch-
thonous transmission of ZIKV for the first time in Brazil [1].
In October 2015, approximately 9 months after the occurrence of the first cases of ZIKV
infection, an unusual increase in the number of children born with microcephaly were
noted in the city of Recife in Brazil’s Northeastern state of Pernumbuco. Similar observations
were reported in the neighbouring states of Paraíba and Rio Grande do Norte. Brain scans of
affected infants, where available, showed an unusual pattern of pathologies, suggesting a new,
thus far not recognised causal agent. An association with ZIKV infection during pregnancy
was hypothesised and the Brazilian Government declared a national public health emergency
on 11 November 2015. The Pan American Health Organization/World Health Organization
(PAHO/WHO) responded by issuing an epidemiological alert; WHO Member States were
asked to report increases of congenital microcephaly and other central nervous system malfor-
mations through the International Health Regulations (IHR) (https://www.who.int/emergencies/
zika-virus/history/en/).
Increasing evidence of an association of ZIKV infection with microcephaly and other
neurological disorders was emerging rapidly, and on 1 February 2016, the WHO declared a
Public Health Emergency of International Concern. Subsequently, in March 2016, the
WHO updated its travel recommendations, advising pregnant women not to travel to areas
with ongoing ZIKV outbreaks. Based on the review of the existing literature, in April 2016,
a scientific consensus was reached that ZIKV infection during pregnancy is a cause of congeni-
tal brain abnormalities, including microcephaly (also referred to as congenital Zika syndrome,
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CZS). By mid-2016, the virus had spread to many other countries
in South and Central America and the Caribbean (https://www.
who.int/emergencies/zika-virus/history/en/).
Whilst the mosquito carrying the virus is not established within
the UK, every year a large number of people, including pregnant
women, visit countries with active ZIKV transmission. In 2015
and 2016, around 3.5 million UK residents travelled to countries
affected by ZIKV (https://www.ons.gov.uk/peoplepopulationand-
community/leisureandtourism/datasets/overseastravelandtourism);
it was estimated that approximately 28% of those were women of
childbearing age. Travel advice for pregnant women or those
planning pregnancy was issued by Public Health England (PHE)
in January 2016; however, there was no noticeable decrease in tra-
vel activity to affected countries in 2016 (https://www.ons.gov.uk/
peoplepopulationandcommunity/leisureandtourism/datasets/overs
eastravelandtourism).
At the early stage of the epidemic, little was known about the
clinical presentation or the level of risk that ZIKV infection posed
to pregnant women travelling to affected areas. In this rapidly
evolving situation, only limited evidence on the range of presen-
tations of CZS was available, often making it necessary to base
guidance and recommendations on single case reports.
In light of this uncertainty and the rapid spread of the virus,
surveillance of newborn babies who were potentially exposed to
ZIKV infection during pregnancy needed to be established
urgently. The aim of the surveillance was to document numbers
of potential cases; to estimate the risk to travellers returning to
the UK from countries where there is ongoing ZIKV transmis-
sion, as well as, if required, aid planning for future services of care.
Several systems exist within the UK to facilitate a rapid
response to public health emergencies and surveillance of rare
congenital infections; the British Paediatric Surveillance Unit
(BPSU), the UK Obstetric Surveillance System (UKOSS) and the
PHE Rare and Imported Pathogens Laboratory (RIPL).
By deploying and adapting these existing systems, and com-
bining their results, we aimed to establish the number of pregnant
women potentially exposed, identify affected children, estimate
the risk to the travelling UK population and to help further
knowledge on the natural history of CZS.
This article describes the methods and findings of surveillance
conducted by the BPSU, UKOSS and RIPL.
Methods
The British Paediatric Surveillance Unit
The BPSU (http://www.rcpch.ac.uk/bpsu), a joint initiative of the
Royal College of Paediatrics and Child Health (RCPCH), PHE
and the UCL Great Ormond Street Institute of Child Health
(ICH), supports surveillance of rare childhood disorders. The
unit also aims to enable organisations to undertake a rapid
response to emerging public health threats and to facilitate
research for improvement in prevention, treatment and planning
of services for rare disorders.
A reporting card (‘Orange Card’) with a list of conditions is
sent electronically each month to over 3300 consultant paediatri-
cians and other specialists in the UK and also (as the only one of
the three surveillance systems) the Republic of Ireland (ROI).
Clinicians complete the card, notifying the BPSU of any cases
of diseases under surveillance or ‘nothing to report’. Reporting
clinicians are asked to complete a questionnaire for cases identi-
fied. PHE has approval under Section 251 of the NHS Act 2006
to process confidential patient information for public health
purposes.
For surveillance of Zika congenital syndrome, all infants ⩽6
months of age with a head circumference >2 standard deviations
below the mean for gestational age and sex (i.e. below the 2nd
centile), or any neurological abnormality requiring investigation,
whose mother has travelled to a country with active Zika trans-
mission during pregnancy or in the 3 months prior to conception
were included. In February 2017, surveillance was extended for a
further 12 months until 31 March 2018 and inclusion criteria
were extended to include infants ⩽12 months of age.
Countries with active Zika transmission were identified through
the European Centre for Disease Prevention and Control (ECDC)
which maintained an up-to-date list of countries with current active
ZIKV transmission and transmission status 9 months previously
(see https://ecdc.europa.eu/en/publications-data/current-zika-
transmission-worldwide and https://ecdc.europa.eu/en/publica
tions-data/zika-transmission-past-nine-months).
Due to the limited existing data, and because the evidence on
the nature, clinical presentation and laboratory diagnosis of the
condition was evolving throughout the course of the outbreak,
confirmation of cases and non-cases was anticipated to be chal-
lenging. Therefore, an expert panel consisting of virologists, pub-
lic health experts, paediatric infectious diseases and neonatal
physicians was convened to discuss each case when reported.
BPSU surveillance commenced on 1 April 2016 and concluded
on 31 March 2018. The case definition described above, including
children ⩽6 months of age, enabled identification of potential
cases born to mothers infected at the end of the first trimester
at the start of the outbreak in April 2015 (see Fig. 1).
A follow-up visit for a developmental assessment was per-
formed at 24 months of age. Due to small numbers, detailed
descriptions of the cases would make patients identifiable; there-
fore, results are presented as aggregates.
The UK Obstetric Surveillance System
UKOSS (https://www.npeu.ox.ac.uk/ukoss), based at the National
Perinatal Epidemiology Unit, University of Oxford, investigates
uncommon disorders in pregnancy. Similar to the BPSU, this
active surveillance system operates as a prospective monthly case-
collection scheme. Each UK hospital with a consultant obstetric
unit receives a monthly email with a list of conditions under sur-
veillance. Clinicians report via an electronic link any cases that
occurred in the previous month, or if none, submit a nil return.
For a case, detailed information is sought through a data collec-
tion form [2]. This methodology has been approved by the
North London Multi-centre Research Ethics Committee R1
(ref10/H0717/20). Unlike the BPSU, this surveillance did not
cover ROI.
Surveillance of CZS aimed to assess the risk of having an
adverse pregnancy outcome after travelling to a country with
active ZIKV transmission. For this purpose, clinicians were
asked to report two different groups of women:
1. Any pregnant woman with a history of travel to a country with
active ZIKV transmission during pregnancy or in the 4 weeks
before conception and no adverse pregnancy outcome.
2. Any pregnant woman with a history of travel to a country with
active ZIKV transmission during pregnancy or in the 4 weeks
before conception with an adverse pregnancy outcome.
2 C. Oeser et al.
https://www.cambridge.org/core/terms. https://doi.org/10.1017/S0950268819001535
Downloaded from https://www.cambridge.org/core. St George's, University of London, on 20 Sep 2019 at 13:29:12, subject to the Cambridge Core terms of use, available at
Countries with active Zika transmission were identified as
above.
Thus, numbers of all pregnant women with a relevant travel
history at an antenatal appointment were reported to UKOSS;
subsequently, detailed information was sought from cases if an
adverse pregnancy outcome was identified.
UKOSS surveillance commenced on 1 March 2016 and was
completed by 28 February 2017. The case definition enabled
inclusion of potential infections occurring at the beginning of
the outbreak, including pre-conception (see Fig. 1). In combin-
ation with surveillance conducted by the BPSU, these case defini-
tions aimed to enable identification of cases over the entirety of
the outbreak.
The Rare and Imported Pathogens Laboratory
RIPL is a PHE specialist centre for advice and diagnosis for unusual
and travel-associated viral and bacterial infections in the UK. It pro-
vides medical and laboratory specialist services to the NHS and
other healthcare providers and is the sole provider for NHS testing
for ZIKV. Both molecular and serology tests are used. (https://www.
gov.uk/guidance/zika-virus-sample-testing-advice). ZIKV testing in
the ROI is not provided by RIPL.
Testing for ZIKV is provided for any patient who has or has
had a rash illness or other symptoms suggestive of ZIKV infection
that began whilst in any country with active ZIKV transmission,
or within 2 weeks of leaving that country. Testing is also provided
for patients presenting with typical Zika-like symptoms whose
male sexual partner had travelled within the last 3 months from
a country with active ZIKV transmission.
As described by Petridou et al. [3], PCR testing has been per-
formed on suspected symptomatic cases since November 2015,
and serological testing was introduced at a later stage, with anti-
body testing performed retrospectively on all earlier samples
received from a symptomatic pregnant woman. Testing of symp-
tomatic returning travellers or sexual contacts for ZIKV is
ongoing.
Detection of ZIKV RNA in any sample is considered diagnos-
tic of infection. Detection of ZIKV IgM and/or IgG is interpreted
as described previously [3].
Results
BPSU: From 1 April 2016 to 31 March 2018, eight suspected cases
were reported from the UK (7) and ROI (1). Of those, one case
was excluded due to not fulfilling the inclusion criteria and
three were excluded as laboratory tests on the mother and baby
were reported as negative for ZIKV. The remaining four possible
cases were followed up until 27 months of age.
Maternal travel destinations included countries in South
America, the Caribbean and Asia.
No diagnostic ZIKV testing was performed for some of the
investigated possible cases as recruitment at the start of the epi-
demic was retrospective, including infants up to the age of 6
months whose mothers had had no symptoms suggestive of
ZIKV infection. Consequently, it is possible that the untested
children did not in fact have congenital ZIKV infection. One of
the infants had laboratory-proven ZIKV infection reported by
RIPL (see below). The four infants presented with a range of clin-
ical features including prematurity, small for gestational age,
micro- and macrocephaly, facial abnormalities and craniofacial
disproportion, intracranial abnormalities (calcifications, cortical/
subcortical atrophy, ventricular dilation and dysmorphia, sube-
pendymal cysts, corona radiata changes, grey matter heterotopia),
nose abnormalities, retinal abnormalities and visual impairment,
tremors, hyperreflexia, cerebral palsy and swallowing difficulties.
Follow-up occurred until 27 months of age and information
on developmental progress was received on all four cases.
Fig. 1. Start of UKOSS and BPSU surveillance in relation to the timeline of the outbreak.
Epidemiology and Infection 3
https://www.cambridge.org/core/terms. https://doi.org/10.1017/S0950268819001535
Downloaded from https://www.cambridge.org/core. St George's, University of London, on 20 Sep 2019 at 13:29:12, subject to the Cambridge Core terms of use, available at
Findings included reports of normal development (1/4) as well as
seizures, delayed language, neuromotor and social skills (3/4), vis-
ual (1/4) and hearing impairment (1/4). Other features noted
were microcephaly and dysmorphic features (2/4).
UKOSS: From 1 March 2016 to 28 February 2017, 827 women
were reported to have travelled from the UK to countries with
active Zika transmission during pregnancy or in the 4 weeks
prior to conception. Of these, 10 were reported to have adverse
outcomes. Data collection forms were received from nine of
these cases. Three of those had symptoms suggestive of ZIKV
infection, four were tested and reported negative for ZIKV. Of
the remaining five (0.6%), three had a miscarriage (3/5, two at
10 weeks of gestational age, for one gestational age was unknown)
and two an intrauterine death (2/5 at 27 and 40 weeks of gesta-
tional age). Travel destinations were South and Central America
and the Caribbean for four cases, and only one case had travelled
to Asia.
RIPL: Detailed results of RIPL surveillance over the 2-year per-
iod 2016–2017 are described elsewhere [3]. In summary, 16 (1%)
of the 1256 pregnant women tested for ZIKV infection were diag-
nosed with either PCR-confirmed infection, seroconversion,
‘probable’ or ‘likely’ infection. Of these, two had a miscarriage
and 14 proceeded to give birth; in one of those, in utero ZIKV
infection was subsequently confirmed.
There were no reports of adverse pregnancy outcomes through
the presumed sexual acquisition of ZIKV infection, and indeed
RIPL identified only a single instance of sexually acquired infec-
tion in the UK [3].
In summary, among 827 pregnant women in the UK, reported
to have been potentially exposed to ZIKV over 1 year, 0.6%
experienced an adverse pregnancy outcome. One per cent of
1256 potentially exposed symptomatic pregnant women tested
in the UK over 2 years were diagnosed with ZIKV infection
and one out of the subsequent 14 live births exposed to ZIKV
in utero became infected. Three infants with abnormalities
potentially attributable to congenital ZIKV infection were identi-
fied by BPSU during 24 months of surveillance. One child with
laboratory-proven ZIKV infection was reported by RIPL as well
as BPSU (Fig. 2).
Discussion
A large proportion of countries in the Southern hemisphere have
reported past or current ZIKV transmission since the start of the
outbreak, including countries or areas in South East Asia and
Africa and the USA. However, since the peak of the epidemic
in 2016, reported ZIKV infections have continuously decreased
in the majority of countries, and in some, virus transmission
has been interrupted (https://ecdc.europa.eu/sites/portal/files/
documents/zika-risk-assessment-9-april-2019.pdf).
Despite many women visiting countries with active Zika trans-
mission during pregnancy, only a small number of adverse out-
comes potentially associated with ZIKV infection during
pregnancy have been reported from the various surveillance sys-
tems. This indicates that, even during the peak of the ZIKV epi-
demic, the risk to the UK travelling population was very low.
All cases reported to the BPSU were evaluated by an expert
group comprised of members of different medical specialties
including virology, neonatology and paediatric infectious diseases;
however, a definitive cause for the presenting abnormalities could
not be determined for some. This is due to a lack of evidence on
the range of presentations of CZS as well as the fact that sero-
logical testing was not performed for those cases identified retro-
spectively at the very beginning of the outbreak and whose
mothers had not had any symptoms suggestive of ZIKV infection.
Moreover, causes for microcephaly and accompanying neuro-
logical abnormities are extensive and include genetic and meta-
bolic conditions as well as infections and teratogenic factors. In
approximately 40% of cases with congenital microcephaly, the
aetiology is unknown [4].
Prompt ZIKV testing and detailed follow-up, including stan-
dardised neurodevelopmental assessments, together with increas-
ing evidence from reports and case studies describing the progress
of children with CZS from countries affected by the outbreak will
guide the further evaluation of possible cases in the future.
Employing two case definitions in the UKOSS surveillance
facilitated active reporting of adverse pregnancy outcomes and
provided an estimate of the number of women who had travelled
to affected countries during pregnancy. However, it needs to be
taken into consideration that this number (n = 827) is likely to be
an underestimate. Based on the provided estimates of numbers of
women of child-bearing age travelling to affected countries and a
general fertility rate of ∼60/1000 (https://www.ons.gov.uk/people
populationandcommunity/birthsdeathsandmarriages/livebirths/
bulletins/birthsummarytablesenglandandwales/previousReleases),
when assuming an average duration of stay of approximately 2
weeks, an estimated 1225 pregnant women would have been
potentially exposed to ZIKV over 1 year, indicating the above cal-
culated risk of 0.6% may be lower.
It was not possible to attribute specific adverse outcomes to
ZIKV infection during pregnancy for these cases identified by
UKOSS, possibly as many of the adverse outcomes occurred
early on in pregnancy, before testing would have been considered.
However, through this method, we were able to establish that the
risk of adverse pregnancy outcomes in pregnant women travelling
to countries affected by ZIKV is low and does not exceed the
expected background rate of either of the adverse pregnancy
Fig. 2. Numbers of adverse pregnancy outcomes potentially associated with ZIKV
infection as reported by the three surveillance systems (note UKOSS surveillance
was conducted over 1 year, RIPL and BPSU over 2 years).
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outcomes at observed gestational ages (11–22% for miscarriages
[5] and 0.4% for intrauterine foetal death [6]).
Testing for ZIKV performed at RIPL over the 2-year period
2016–2017 showed that the number of apparently symptomatic
women testing positive after potential exposure to ZIKV through
travel is also low (1%). This highlights that, even at the time of the
epidemic, the likelihood of a pregnant traveller acquiring ZIKV
infection was very small. Only one of 14 children born to
women diagnosed with ZIKV also acquired the infection.
The presence of established systems provided a platform to
enable the timely organisation of surveillance of CZS in returning
travellers in the UK. Laboratory surveillance was available from
early on in the outbreak, UKOSS surveillance was established
within 1 month and BPSU surveillance within 2 months of the
WHO declaration of the Public Health Emergency of
International Concern. The variation and minimal overlap of
the results of these surveillance systems demonstrate the import-
ance of considering different approaches of surveillance, spanning
the entire time period relevant to the outbreak and encompassing
several disciplines with distinct case definitions as employed here,
particularly when faced with the challenges of a previously
unknown infection.
Combining results of the different surveillance systems con-
firmed that the risk of adverse pregnancy outcomes because of
ZIKV infection overall is low. Employing established surveillance
systems at an early stage of the outbreak facilitated information on
the risk to the travelling UK population. The prompt and effective
response of these separate surveillance systems provided reassur-
ance that suitable approaches are in place to respond to similar
threats in a coordinated effort in the future.
International Networks such as the International Network of
Paediatric Surveillance Units (INOPSU) and International
Network of Obstetric Survey Systems (INOSS) of those countries
with similar paediatric and obstetric surveillance systems exist and
could be used for rapid international studies of congenital infec-
tions in the future.
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